Potential suitors have been jockeying for position in an attempt to buy Merck's (NYSE:MRK) consumer care division, which is known for products like coppertone sunscreen, Claritin (an allergy medicine), and Dr. Scholl's foot care. Bids may come in as high as $14 billion for the division, which generated $1.9 billion in sales last year.
The proposed sale is part of a broader trend that we've been seeing in health care, as big pharma companies divest divisions that aren't central to their business models to free up cash for R&D and M&A in areas of particular expertise.
In this video, from Tuesday's Market Checkup, Motley Fool health care analysts Michael Douglass and David Williamson discuss potential suitors and the implications of the massive potential deal.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
David Williamson owns shares of Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.